AdaptHealth Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
A North Carolina federal court preliminarily approved a $14.3M settlement for AdaptHealth Corp. regarding overbilling claims for returned medical equipment.
McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.
AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.
Over the past 7 days, alphai's AI scored 1 news story mentioning AHCO (AdaptHealth Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent AHCO coverage spans earnings, insider activity and financial news.
In the last 30 days, AHCO insiders filed 3 SEC Form 4 transactions — 3 purchases ($395K) and no sales. The most active reporter was WOLF DALE B with 2 filings.
The settlement may lead to a modest negative impact on AdaptHealth's share price due to legal expense and reputational risk.
Weak revenue growth and missed guidance cause sharp sell‑off.
Guidance reset and margin pressure from contract transition and input price lift downside risk to 2026 earnings and cash flow.
The deal linkage can create read-through trading in AHCO, but the article does not provide deal terms or new AHCO-specific disclosures.
Earnings call discloses a clear profit headwind and a major guidance reset, plus cash flow weakness and leverage, which can drive near-term repricing.
alphai scores every news story that mentions AHCO with an AI model for sentiment and relevance, and aggregates insider trades from AdaptHealth Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A North Carolina federal court preliminarily approved a $14.3M settlement for AdaptHealth Corp. regarding overbilling claims for returned medical equipment.
1 min readMcKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.
3 min readAdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.
6 min readU.S. indexes drifted lower as crude oil and interest rates were mostly flat, with investors awaiting the July CPI report. FactSet data for 88% of S&P 500 firms showed 86% positive earnings surprises and 76% positive revenue surprises. Nasdaq fell 0.6% to 26,445, S&P 500 0.3% to 7,728, Dow 0.3% to 53,791. CoreWeave (CRWV) and Super Micro (SMCI) report after the close; Nvidia (NVDA) and Intel (INTC) were also discussed.
6 min readAdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.
7 min readAdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.
6 min readAdaptHealth Corp. (NASDAQ:AHCO) director Kenneth A. Samet bought 23,500 shares on Aug. 6, 2026 at $6.38 each for about $149,930. After the purchase, he beneficially owns 48,569 shares. The stock is near its 52-week low. The company recently reported a Q2 adjusted loss of $0.99 vs a $0.15 expected profit, with revenue of $740.3 million.
3 min readSAMET KENNETH A purchased 23,500 shares of AdaptHealth Corp. (AHCO) at $6.38 ($0.15M total) on 2026-08-06.
2 min readWOLF DALE B purchased 20,000 indirectly-held shares of AdaptHealth Corp. (AHCO) at $5.86 ($0.12M total) on 2026-08-07.
1 min readWOLF DALE B purchased 20,000 shares of AdaptHealth Corp. (AHCO) at $6.37 ($0.13M total) on 2026-08-06.
1 min read
